Cabozantinib CAS 849217-68-1

Product Description:

Product Name: Cabozantinib CAS NO: 849217-68-1

Synonyms:

[14C]-Cabozantinib;

Cometriq;

Chemical & Physical Properties:

Appearance: White powder

Assay :≥99.0%

Density: 1.397 g/cm3

Boiling Point: 758.075℃ at 760 mmHg

Flash Point: 412.269℃

Refractive Index: 1.688

Safety Information:

HS Code: 2933499090

Cabozantinib, marketed under the trade name Cabometyx among others, is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc.

Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib is approved by the U.S. FDA for medullary thyroid cancer. and advanced renal cell carcinoma in people who have received prior anti-angiogenic therapy. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, and hepatocellular cancers.

Cabozantinib will be distributed in Europe by the French pharmaceutical company Ipsen after a collaboration was reached with Exelixis in March of 2016.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.